688443 智翔金泰-U
已收盘 05-21 15:00:01
资讯
新帖
简况
每周股票复盘：智翔金泰（688443）GR1803获临床试验批准
证券之星 · 05-17
每周股票复盘：智翔金泰（688443）GR1803获临床试验批准
智翔金泰(688443.SH)在研产品GR1803注射液(皮下注射)临床试验申请获批
智通财经 · 05-14
智翔金泰(688443.SH)在研产品GR1803注射液(皮下注射)临床试验申请获批
智翔金泰（688443）披露召开2025年年度暨2026年第一季度业绩说明会公告，5月13日股价下跌1.12%
证券之星 · 05-13
智翔金泰（688443）披露召开2025年年度暨2026年第一季度业绩说明会公告，5月13日股价下跌1.12%
股市必读：智翔金泰年报 - 第四季度单季净利润同比增长19.08%
证券之星 · 05-06
股市必读：智翔金泰年报 - 第四季度单季净利润同比增长19.08%
每周股票复盘：智翔金泰（688443）一季度营收增233.63%
证券之星 · 05-02
每周股票复盘：智翔金泰（688443）一季度营收增233.63%
智翔金泰（688443）2026年一季报简析：增收不增利，盈利能力上升
证券之星 · 05-01
智翔金泰（688443）2026年一季报简析：增收不增利，盈利能力上升
智翔金泰商业化蓄势起跑：一季度营收同比暴增超2倍 四款新药正冲刺上市
中金财经 · 04-30
智翔金泰商业化蓄势起跑：一季度营收同比暴增超2倍 四款新药正冲刺上市
图解智翔金泰年报：第四季度单季净利润同比增长19.08%
证券之星 · 04-30
图解智翔金泰年报：第四季度单季净利润同比增长19.08%
智翔金泰（688443）披露2025年年度股东会通知，4月29日股价上涨0.03%
证券之星 · 04-29
智翔金泰（688443）披露2025年年度股东会通知，4月29日股价上涨0.03%
每周股票复盘：智翔金泰（688443）授出786.97万股限制性股票
证券之星 · 04-26
每周股票复盘：智翔金泰（688443）授出786.97万股限制性股票
智翔金泰跌2.47% 连亏5年2023年上市募资34.7亿元
中金财经 · 04-20
智翔金泰跌2.47% 连亏5年2023年上市募资34.7亿元
智翔金泰跌3.59% 连亏5年2023年上市募资34.7亿元
中金财经 · 04-17
智翔金泰跌3.59% 连亏5年2023年上市募资34.7亿元
智翔金泰（688443）披露2026年限制性股票激励计划（草案），4月7日股价上涨2.52%
证券之星 · 04-07
智翔金泰（688443）披露2026年限制性股票激励计划（草案），4月7日股价上涨2.52%
每周股票复盘：智翔金泰（688443）推812.97万股限制性股票激励计划
证券之星 · 04-05
每周股票复盘：智翔金泰（688443）推812.97万股限制性股票激励计划
智翔金泰股权激励“对表”市场预期：营收考核对标券商研报 新管线储备设硬门槛
中金财经 · 04-03
智翔金泰股权激励“对表”市场预期：营收考核对标券商研报 新管线储备设硬门槛
智翔金泰(688443.SH)拟推2026年限制性股票激励计划
智通财经 · 04-03
智翔金泰(688443.SH)拟推2026年限制性股票激励计划
智翔金泰跌1.01% 连亏5年2023年上市募资34.7亿元
中金财经 · 03-25
智翔金泰跌1.01% 连亏5年2023年上市募资34.7亿元
每周股票复盘：智翔金泰（688443）归还5亿元临时补流募集资金
证券之星 · 03-22
每周股票复盘：智翔金泰（688443）归还5亿元临时补流募集资金
智翔金泰（688443）披露归还临时补充流动资金的募集资金公告，3月16日股价下跌0.56%
证券之星 · 03-16
智翔金泰（688443）披露归还临时补充流动资金的募集资金公告，3月16日股价下跌0.56%
每周股票复盘：智翔金泰（688443）调整募投项目资金
证券之星 · 03-08
每周股票复盘：智翔金泰（688443）调整募投项目资金
暂无数据
公司概况
公司名称：
重庆智翔金泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2023-06-20
主营业务：
重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产及商业化。公司的主要产品是赛立奇单抗（GR1501）、斯乐韦米单抗（GR1801）、唯康度塔单抗（GR2001）、泰利奇拜单抗（GR1802）、纬利妥米单抗（GR1803）。截至报告期末，公司已就自身研发的创新成果积极开展知识产权保护，已取得专利授权61项。
发行价格：
37.88
{"stockData":{"symbol":"688443","market":"SH","secType":"STK","nameCN":"智翔金泰-U","latestPrice":29.39,"timestamp":1779346801000,"preClose":29.25,"halted":0,"volume":6288546,"delay":0,"changeRate":0.0048,"floatShares":117000000,"shares":367000000,"eps":-1.5391,"marketStatus":"已收盘","change":0.14,"latestTime":"05-21 15:00:01","open":29.25,"high":31.39,"low":29.25,"amount":191000000,"amplitude":0.0732,"askPrice":29.39,"askSize":7,"bidPrice":29.37,"bidSize":65,"shortable":0,"etf":0,"ttmEps":-1.5391,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779413400000},"marketStatusCode":5,"adr":0,"adjPreClose":29.25,"symbolType":"stock_kcb","openAndCloseTimeList":[[1779327000000,1779334200000],[1779339600000,1779346800000]],"highLimit":32.18,"lowLimit":26.33,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":366680000,"isCdr":false,"pbRate":7.51,"roa":"--","roe":"--","epsLYR":-1.46,"committee":0.767347,"marketValue":10777000000,"turnoverRate":0.0539,"status":0,"afterMarket":{"amount":0,"volume":0,"close":29.39,"buyVolume":0,"sellVolume":0,"time":1779348837558,"indexStatus":"已收盘 05-21 15:30:00","preClose":29.25},"floatMarketCap":3429000000},"requestUrl":"/m/hq/s/688443/tweets","defaultTab":"tweets","newsList":[{"id":"2636062738","title":"每周股票复盘：智翔金泰（688443）GR1803获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636062738","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636062738?lang=zh_cn&edition=full","pubTime":"2026-05-17 05:00","pubTimestamp":1778965237,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，智翔金泰报收于30.05元，较上周的30.77元下跌2.34%。本周，智翔金泰5月12日盘中最高价报31.81元。自愿披露关于GR1803注射液获得药物临床试验批准通知书的公告重庆智翔金泰生物制药股份有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，其自主研发的GR1803注射液获准在复发性/难治性多发性骨髓瘤患者中开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635619718","title":"智翔金泰(688443.SH)在研产品GR1803注射液(皮下注射)临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2635619718","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635619718?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:37","pubTimestamp":1778751467,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研产品GR1803注射液临床试验申请获得批准。公告显示，GR1803注射液是一款由公司自主研发的双特异性抗体药物，作用靶点为BCMA和CD3，注册分类为治疗用生物制品1类。本次将GR1803注射液的给药方式拓展为皮下注射，可提高患者的用药便利性与依从性，减少就诊耗时及医疗资源占用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智翔金泰(688443.SH)在研产品GR1803注射液(皮下注射)临床试验申请获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635173594","title":"智翔金泰（688443）披露召开2025年年度暨2026年第一季度业绩说明会公告，5月13日股价下跌1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635173594","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635173594?lang=zh_cn&edition=full","pubTime":"2026-05-13 22:45","pubTimestamp":1778683518,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，智翔金泰报收于30.85元，较前一交易日下跌1.12%，最新总市值为113.12亿元。该股当日开盘31.15元，最高31.42元，最低29.85元，成交额达1.37亿元，换手率为3.84%。近日，重庆智翔金泰生物制药股份有限公司发布《关于召开2025年年度暨2026年第一季度业绩说明会的公告》。公告显示，公司将于2026年5月22日15:00-16:00通过网络互动方式在“价值在线”平台召开业绩说明会，介绍公司2025年年度及2026年第一季度经营业绩和发展战略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300045947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633292423","title":"股市必读：智翔金泰年报 - 第四季度单季净利润同比增长19.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633292423","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633292423?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:48","pubTimestamp":1778014091,"startTime":"0","endTime":"0","summary":"业绩披露要点财务报告智翔金泰2025年主营收入2.31亿元，同比上升666.66%；归母净利润-5.36亿元，同比上升32.81%；扣非净利润-5.79亿元，同比上升28.06%。2025年第四季度单季主营收入2317.15万元，同比增长31.6%；单季归母净利润-2.03亿元，同比增长19.08%；单季扣非净利润-2.09亿元，同比增长17.83%。国泰海通证券股份有限公司关于重庆智翔金泰生物制药股份有限公司2026年度日常关联交易预计的核查意见公司预计2026","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632628377","title":"每周股票复盘：智翔金泰（688443）一季度营收增233.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632628377","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632628377?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:16","pubTimestamp":1777670175,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，智翔金泰报收于29.62元，较上周的31.45元下跌5.82%。本周，智翔金泰4月27日盘中最高价报31.75元。本周关注点来自业绩披露要点：智翔金泰2026年一季度主营收入6724.67万元，同比上升233.63%。股本股东变化截至2026年3月31日，智翔金泰股东户数为1.28万户，较2025年12月31日增加215户，增幅1.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632660260","title":"智翔金泰（688443）2026年一季报简析：增收不增利，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2632660260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632660260?lang=zh_cn&edition=full","pubTime":"2026-05-01 06:50","pubTimestamp":1777589416,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期智翔金泰发布2026年一季报。截至本报告期末，公司营业总收入6724.67万元，同比上升233.63%，归母净利润-1.49亿元，同比下降23.76%。本报告期智翔金泰盈利能力上升，毛利率同比增幅4.74%，净利率同比增幅62.91%。本次财报公布的各项数据指标表现一般。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100007334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631859476","title":"智翔金泰商业化蓄势起跑：一季度营收同比暴增超2倍 四款新药正冲刺上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2631859476","media":"中金财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631859476?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:17","pubTimestamp":1777537023,"startTime":"0","endTime":"0","summary":"中国网财经4月30日讯 昨日晚间，智翔金泰发布2025年度及2026年一季度财报。2026年一季度，公司实现营收约6724.67万元，同比增长233.63%；归母净利润-1.49亿元，同比增亏23.76%。 中国网财经记者注意到，智翔金泰虽营收动辄几倍增长，利润却波动较大，且仍未扭亏。智翔金泰2026年一季报显示，当期公司营收同比暴增233.63%，即为此原因所致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260430/32193941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688443","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631444525","title":"图解智翔金泰年报：第四季度单季净利润同比增长19.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631444525","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631444525?lang=zh_cn&edition=full","pubTime":"2026-04-30 01:00","pubTimestamp":1777482052,"startTime":"0","endTime":"0","summary":"证券之星消息，智翔金泰2025年年报显示，当年度公司主营收入2.31亿元，同比上升666.66%；归母净利润-5.36亿元，同比上升32.81%；扣非净利润-5.79亿元，同比上升28.06%；其中2025年第四季度，公司单季度主营收入2317.15万元，同比上升31.6%；单季度归母净利润-2.03亿元，同比上升19.08%；单季度扣非净利润-2.09亿元，同比上升17.83%；负债率47.06%，投资收益882.6万元，财务费用-446.41万元，毛利率93.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000003214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631054332","title":"智翔金泰（688443）披露2025年年度股东会通知，4月29日股价上涨0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631054332","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631054332?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:28","pubTimestamp":1777472887,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘，智翔金泰报收于30.8元，较前一交易日上涨0.03%，最新总市值为112.94亿元。该股当日开盘30.97元，最高31.23元，最低30.28元，成交额达9261.56万元，换手率为2.59%。近日，重庆智翔金泰生物制药股份有限公司发布《关于召开2025年年度股东会的通知》。公告显示，公司将于2026年6月1日召开2025年年度股东会，会议采取现场投票与网络投票相结合方式，网络投票通过上海证券交易所系统进行。股权登记日为2026年5月25日，A股股东均可参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900069351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630802377","title":"每周股票复盘：智翔金泰（688443）授出786.97万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2630802377","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630802377?lang=zh_cn&edition=full","pubTime":"2026-04-26 04:43","pubTimestamp":1777149789,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，智翔金泰报收于31.45元，较上周的31.13元上涨1.03%。公司公告汇总北京市万商天勤律师事务所出具法律意见书，确认重庆智翔金泰生物制药股份有限公司2026年限制性股票激励计划首次授予相关事宜的批准程序合法合规。重庆智翔金泰生物制药股份有限公司公布2026年限制性股票激励计划首次授予激励对象名单，共计812.97万股，占公司股本总额的2.22%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600002011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628253743","title":"智翔金泰跌2.47% 连亏5年2023年上市募资34.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628253743","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628253743?lang=zh_cn&edition=full","pubTime":"2026-04-20 16:45","pubTimestamp":1776674703,"startTime":"0","endTime":"0","summary":"中国经济网北京4月20日讯 智翔金泰 今日股价下跌，截至收盘，该股报30.36元，跌幅2.47%。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14万元。 智翔金泰首次公开发行股票的发行费用合计18,143.70万元(不含税)，其中，保荐承销费16,495.98万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260420/32156982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628274446","title":"智翔金泰跌3.59% 连亏5年2023年上市募资34.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628274446","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628274446?lang=zh_cn&edition=full","pubTime":"2026-04-17 17:21","pubTimestamp":1776417710,"startTime":"0","endTime":"0","summary":"中国经济网北京4月17日讯 智翔金泰 今日股价下跌，截至收盘，该股报31.13元，跌幅3.59%。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14万元。 智翔金泰首次公开发行股票的发行费用合计18,143.70万元(不含税)，其中，保荐承销费16,495.98万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260417/32151826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625399949","title":"智翔金泰（688443）披露2026年限制性股票激励计划（草案），4月7日股价上涨2.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625399949","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625399949?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:42","pubTimestamp":1775554942,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，智翔金泰报收于27.7元，较前一交易日上涨2.52%，最新总市值为101.57亿元。该股当日开盘27.09元，最高28.86元，最低26.65元，成交额达1.85亿元，换手率为5.67%。近日，重庆智翔金泰生物制药股份有限公司发布2026年限制性股票激励计划（草案），拟授予限制性股票总数812.97万股，占公司股本总额的2.22%，其中首次授予786.97万股，预留26万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625195736","title":"每周股票复盘：智翔金泰（688443）推812.97万股限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2625195736","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625195736?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:55","pubTimestamp":1775328910,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，智翔金泰报收于27.02元，较上周的26.11元上涨3.49%。本周关注点公司公告汇总：智翔金泰拟授予812.97万股限制性股票，占总股本2.22%。公司公告汇总重庆智翔金泰生物制药股份有限公司制定《2026年限制性股票激励计划实施考核管理办法》，旨在完善治理结构，建立长效激励机制，考核涵盖公司层面与个人层面。公司公布2026年限制性股票激励计划首次授予激励对象名单，总计812.97万股，占总股本2.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537650","title":"智翔金泰股权激励“对表”市场预期：营收考核对标券商研报 新管线储备设硬门槛","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537650","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624537650?lang=zh_cn&edition=full","pubTime":"2026-04-03 20:47","pubTimestamp":1775220423,"startTime":"0","endTime":"0","summary":"中国网财经4月3日讯 在首款产品赛立奇单抗进入新版国家医保目录，并有四款新药正冲刺上市之际，今日下午，智翔金泰发布股权激励计划，团结各方，对公司业绩，尤其是商业化销售关键指标——营收及新研发管线的储备进度作出特别激励。他称，考虑到智翔金泰当前的产品上市及进入医保的节奏，业绩考核目标值的设置也是相对合理的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260403/32125484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624654565","title":"智翔金泰(688443.SH)拟推2026年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2624654565","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624654565?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:46","pubTimestamp":1775213175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰(688443.SH)披露2026年限制性股票激励计划(草案)，拟授予激励对象的限制性股票数量为812.97万股，约占激励计划草案公布日公司股本总额的2.22%。其中，首次授予限制性股票786.97万股，首次授予激励对象共计99人，授予价格均为14.21元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622029788","title":"智翔金泰跌1.01% 连亏5年2023年上市募资34.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622029788","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622029788?lang=zh_cn&edition=full","pubTime":"2026-03-25 17:15","pubTimestamp":1774430101,"startTime":"0","endTime":"0","summary":"中国经济网北京3月25日讯 智翔金泰 今日股价下跌，截至收盘，该股报25.37元，跌幅1.01%。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14万元。 智翔金泰首次公开发行股票的发行费用合计18,143.70万元(不含税)，其中，保荐承销费16,495.98万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260325/32097641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621918317","title":"每周股票复盘：智翔金泰（688443）归还5亿元临时补流募集资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2621918317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621918317?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:18","pubTimestamp":1774120694,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，智翔金泰报收于25.68元，较上周的26.7元下跌3.82%。本周，智翔金泰3月17日盘中最高价报27.55元。本周关注点公司公告汇总：智翔金泰已全额归还50,000万元临时补充流动资金的募集资金。公司公告汇总关于归还临时补充流动资金的募集资金的公告重庆智翔金泰生物制药股份有限公司于2025年4月25日召开董事会及监事会，审议通过使用不超过50,000万元闲置募集资金临时补充流动资金，使用期限不超过12个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200001262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619246403","title":"智翔金泰（688443）披露归还临时补充流动资金的募集资金公告，3月16日股价下跌0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619246403","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619246403?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:55","pubTimestamp":1773672916,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，智翔金泰报收于26.55元，较前一交易日下跌0.56%，最新总市值为97.35亿元。该股当日开盘26.45元，最高26.65元，最低26.02元，成交额达6022.75万元，换手率为1.96%。近日，重庆智翔金泰生物制药股份有限公司披露《关于归还临时补充流动资金的募集资金的公告》。截至2026年3月16日，公司已将上述50,000万元全部归还至募集资金专用账户，使用期限未超过董事会批准期限，并已通知保荐机构及保荐代表人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600037256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617668044","title":"每周股票复盘：智翔金泰（688443）调整募投项目资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617668044?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:45","pubTimestamp":1772909113,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，智翔金泰报收于26.84元，较上周的27.21元下跌1.36%。本周，智翔金泰3月2日盘中最高价报27.35元。智翔金泰当前最新总市值98.42亿元，在生物制品板块市值排名29/51，在两市A股市值排名2065/5190。本周关注点公司公告汇总：智翔金泰股东大会通过部分募投项目间资金调整暨新增子项目议案。邓纲先生当选为公司第二届董事会独立董事。北京市万商天勤律师事务所对本次会议出具了法律意见书，认为会议召集、召开程序及表决结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779392388399,"stockEarnings":[{"period":"1week","weight":-0.0229},{"period":"1month","weight":-0.0332},{"period":"3month","weight":0.0356},{"period":"6month","weight":0.0971},{"period":"1year","weight":0.0177},{"period":"ytd","weight":0.0789}],"compareEarnings":[{"period":"1week","weight":-0.0241},{"period":"1month","weight":-0.0019},{"period":"3month","weight":-0.0012},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2036},{"period":"ytd","weight":0.0273}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智翔金泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12843人(较上一季度增加1.70%)","perCapita":"9085股","listingDate":"2023-06-20","address":"重庆市巴南区麻柳大道699号2号楼A区","registeredCapital":"36668万元","survey":" 重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产及商业化。公司的主要产品是赛立奇单抗（GR1501）、斯乐韦米单抗（GR1801）、唯康度塔单抗（GR2001）、泰利奇拜单抗（GR1802）、纬利妥米单抗（GR1803）。截至报告期末，公司已就自身研发的创新成果积极开展知识产权保护，已取得专利授权61项。","listedPrice":37.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智翔金泰-U(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智翔金泰-U(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智翔金泰-U,688443,智翔金泰-U股票,智翔金泰-U股票老虎,智翔金泰-U股票老虎国际,智翔金泰-U行情,智翔金泰-U股票行情,智翔金泰-U股价,智翔金泰-U股市,智翔金泰-U股票价格,智翔金泰-U股票交易,智翔金泰-U股票购买,智翔金泰-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智翔金泰-U(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智翔金泰-U(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}